A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

Overall Complete Hematologic Response (HemCR) Rate

Overall HemCR rate is defined as percentage of participants who achieve HemCR during or after the study treatment.

Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)

HemCR Rate

HemCR rate at 6 month is defined as percentage of participants who achieve HemCR at 6 month during or after the study treatment.

Time frame: At 6 months

Very Good Partial Response (VGPR) or Better Rate

Hematologic greater than or equal to (\>=) VGPR rate is defined as percentage of participants who achieve hematologic response of VGPR or better.

Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)

Time to HemCR or (VGPR or Better)

For participants who achieve HemCR (or \>=VGPR), time to HemCR (or \>=VGPR) is defined as the time between the date of first study treatment and the first efficacy evaluation at which the participant has met all criteria for hematologic complete response (CR) (or \>=VGPR).

Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)

Duration of Response (HemCR and VGPR or Better)

For participants who achieve HemCR (or \>=VGPR), duration of HemCR (or \>=VGPR) is defined as the time between the date of initial documentation of HemCR (or \>=VGPR) to the date of first documented evidence of hematologic progressive disease or death, whichever comes first.

Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)

Organ Response Rate (OrRR)

Organ response rate is defined as the percentage of participants who achieve organ response in each corresponding organ (kidney, heart, liver).

Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)

Overall Survival (OS)

OS is measured from the date of first study treatment to the date of the participant's death.

Time frame: Until Cycle 12 or Month 12 (whichever occurs later)

Time to Subsequent Therapy

Time to subsequent therapy for amyloid light chain (AL) amyloidosis is defined as the time from the date of first study treatment to the start date of subsequent AL amyloidosis (non-protocol) treatment.

Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)

Number of Participants with Adverse Events (AEs) by Severity

Number of participants with AEs by severity will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.

Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)

Serum Concentration of Daratumumab

Serum samples will be analyzed to determine concentrations of daratumumab.

Time frame: Up to 3 years

Number of Participants with Antibodies to Daratumumab

Number of participants with antibodies to daratumumab will be reported.

Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)

Number of Participants with Antibodies to Recombinant Human Hyaluronidase PH20 Enzyme (rHuPH20)

Number of participants with antibodies to rHuPH20 will be reported.

Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)

Change from Baseline in Clinical Signs and Symptoms Score of Cardiac AL Amyloidosis

Change from baseline in clinical signs and symptoms score of cardiac AL amyloidosis will be reported.

Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)